Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Cazzola

Showing results (521-530 of 645) with videos related to

Pageof 65
Sort By:
Cancer Genetics|July 4, 2012
Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndromeIrene Dambruoso, Marina Boni, Marianna Rossi, et al.
British Journal of Haematology|June 13, 2002
Natural history of juvenile haemochromatosisMarco De Gobbi, Antonella Roetto, Alberto Piperno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2007
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromesLuca Malcovati, Ulrich Germing, Andrea Kuendgen, et al.
Blood|April 12, 2007
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutationFrancesco Passamonti, Maria Luigia Randi, Elisa Rumi, et al.
British Journal of Haematology|October 6, 2007
Gene expression profiling of CD34+ cells in patients with the 5q- syndromeJacqueline Boultwood, Andrea Pellagatti, Helen Cattan, et al.
American Journal of Respiratory and Critical Care Medicine|May 26, 2023
An Update on Outcomes for COPD Pharmacological Trials: A COPD Investigators Report - Reassessment of the 2008 American Thoracic Society/European Respiratory Society Statement on Outcomes for COPD Pharmacological TrialsMario Cazzola, Paola Rogliani, Peter J Barnes, et al.
Blood Cancer Journal|December 9, 2017
CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profilesRoberta Zini, Paola Guglielmelli, Daniela Pietra, et al.
Blood|February 26, 2004
Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosisCarmela Lanzara, Antonella Roetto, Filomena Daraio, et al.
Blood|March 19, 2015
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosisNicolaus Kröger, Toni Giorgino, Bart L Scott, et al.
Blood|July 4, 2013
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSGAndrea Schnaiter, Peter Paschka, Marianna Rossi, et al.
Pageof 65

Showing results (521-530 of 645) with videos related to

Sort By:
Pageof 65
Cancer Genetics|July 4, 2012
Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndromeIrene Dambruoso, Marina Boni, Marianna Rossi, et al.
British Journal of Haematology|June 13, 2002
Natural history of juvenile haemochromatosisMarco De Gobbi, Antonella Roetto, Alberto Piperno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2007
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromesLuca Malcovati, Ulrich Germing, Andrea Kuendgen, et al.
Blood|April 12, 2007
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutationFrancesco Passamonti, Maria Luigia Randi, Elisa Rumi, et al.
British Journal of Haematology|October 6, 2007
Gene expression profiling of CD34+ cells in patients with the 5q- syndromeJacqueline Boultwood, Andrea Pellagatti, Helen Cattan, et al.
American Journal of Respiratory and Critical Care Medicine|May 26, 2023
An Update on Outcomes for COPD Pharmacological Trials: A COPD Investigators Report - Reassessment of the 2008 American Thoracic Society/European Respiratory Society Statement on Outcomes for COPD Pharmacological TrialsMario Cazzola, Paola Rogliani, Peter J Barnes, et al.
Blood Cancer Journal|December 9, 2017
CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profilesRoberta Zini, Paola Guglielmelli, Daniela Pietra, et al.
Blood|February 26, 2004
Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosisCarmela Lanzara, Antonella Roetto, Filomena Daraio, et al.
Blood|March 19, 2015
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosisNicolaus Kröger, Toni Giorgino, Bart L Scott, et al.
Blood|July 4, 2013
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSGAndrea Schnaiter, Peter Paschka, Marianna Rossi, et al.
Pageof 65